



Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Shunsuke Kondo¹ · Masaomi Tajimi² · Tomohiko Funai² · Koichi Inoue² · Hiroya Asou² · Vinay Kumar Ranka³ · Volker Wacheck⁴ · Toshihiko Doi⁵

Published online: 7 September 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction: Invest New Drugs

<https://doi.org/10.1007/s10637-020-00968-5>

The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi, was originally published electronically on the publisher's internet portal on 23 June 2020 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on August 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10637-020-00968-5>

✉ Shunsuke Kondo
shkondo@ncc.go.jp

¹ Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan

² Eli Lilly Japan K.K, Kobe, Japan

³ Eli Lilly Services India Private Limited, Bengaluru, India

⁴ Eli Lilly GmbH, Vienna, Austria

⁵ Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan